BrainStorm Cell Therapeutics Says Data Show Treatment With NurOwn Significantly Reduces NfL, A Key Biomarker Of Neurodegeneration
Portfolio Pulse from Benzinga Newsdesk
BrainStorm Cell Therapeutics has announced that data shows treatment with NurOwn significantly reduces NfL, a key biomarker of neurodegeneration. The treatment also elevated markers of neuroprotection and lowered markers of neuroinflammation.
July 07, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BrainStorm's NurOwn treatment has shown promising results in reducing neurodegeneration, which could potentially boost the company's stock.
The positive results from the NurOwn treatment trials indicate a potential breakthrough in neurodegeneration treatment. This could lead to increased demand for BrainStorm's products, potentially driving up the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100